Bobrowski Alexej, Klebs Sven, Alibone Marco, Bovy Leonore, Häckl Dennis, Fleck Thilo, Stiller Brigitte
Department of Congenital Heart Defects and Pediatric Cardiology, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Freiburg, Germany.
Novartis Pharma GmbH, Nuremberg, Germany.
ESC Heart Fail. 2024 Dec;11(6):4371-4380. doi: 10.1002/ehf2.15043. Epub 2024 Sep 3.
Paediatric chronic heart failure (CHF) is associated with significant morbidity. The aim of this study was to describe paediatric CHF epidemiology in Germany.
This is a retrospective cross-sectional analysis of anonymized healthcare claims data in the InGef database. This database includes longitudinal data from a representative sample of the German population of approximately 4.8 million insured members. We included individuals <18 years from 2016 to 2021. CHF was defined by ≥2 diagnoses in different quarters of the year as inpatient or outpatient, using ICD-10-GM codes I50.- or P29.0. The number of eligible children in the database was 674 462 in 2016 and 660 692 in 2021. Prevalence of CHF per 100 000 children was 20.6 [95% confidence interval (CI), 17.3-24.3] in 2016 and 19.4 (95% CI, 16.2 to 23.0) in 2021. Incidence per 100 000 children was 9.6 (95% CI, 7.4 to 12.3) in 2016 and 7.6 (95% CI, 5.6 to 10.0) in 2021 for newly diagnosed CHF. All-cause hospitalizations occurred in 47.3% to 57.7% of children with CHF per year. Up to 6.3% of children with CHF were hospitalized, coded primarily for heart failure. Mortality of children with CHF was <5 death per year in the studied population. In 128 children with CHF in 2021, the most common ICD-coded comorbidities were congenital malformations of cardiac septa (57.8%), atrial septal defect (44.5%), congenital malformations of the great arteries (43.0%) and ventricular septal defect (32.0%). Coded treatment modalities for paediatric CHF in 2021 included angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers (18.8%), beta-blockers (17.2%), mineralocorticoid receptor antagonists (14.8%) and surgical procedures (13.3%).
This representative cohort study reveals a relatively high incidence proportion. Approximately half of the children with CHF are hospitalized annually while mortality is low.
小儿慢性心力衰竭(CHF)与显著的发病率相关。本研究旨在描述德国小儿CHF的流行病学情况。
这是一项对InGef数据库中匿名医疗索赔数据的回顾性横断面分析。该数据库包含来自德国约480万参保成员代表性样本的纵向数据。我们纳入了2016年至2021年18岁以下的个体。CHF通过使用ICD - 10 - GM编码I50.-或P29.0,在一年中不同季度作为住院或门诊患者的≥2次诊断来定义。2016年数据库中符合条件的儿童数量为674462名,2021年为660692名。2016年每10万名儿童中CHF的患病率为20.6[95%置信区间(CI),17.3 - 24.3],2021年为19.4(95%CI,16.2至23.0)。2016年每10万名儿童中新诊断CHF的发病率为9.6(95%CI,7.4至12.3),2021年为7.6(95%CI,5.6至10.0)。每年有47.3%至57.7%的CHF儿童发生全因住院治疗。高达6.3%的CHF儿童因主要编码为心力衰竭而住院。在研究人群中,CHF儿童的死亡率每年<5例。在2021年患有CHF的128名儿童中,最常见的ICD编码合并症是心脏间隔先天性畸形(57.8%)、房间隔缺损(44.5%)、大动脉先天性畸形(43.0%)和室间隔缺损(32.0%)。2021年小儿CHF编码治疗方式包括血管紧张素转换酶抑制剂或血管紧张素II 1型受体阻滞剂(18.8%)、β受体阻滞剂(17.2%)、盐皮质激素受体拮抗剂(14.8%)和外科手术(13.3%)。
这项代表性队列研究揭示了相对较高的发病率比例。每年约有一半CHF儿童住院,但死亡率较低。